Recent news on Recombivax

'No link' between autism and mercury-containing vaccines  -  May 16, 2007
BiopharmaReporter.com,These include Merck & Co's Recombivax-HB (thimerosal free), GlaxoSmithKline's Engerix-B (trace thimerosal), and Aventis-Pasteur's Tripedia (trace

Dynavax Stock Rises After Positive Trial  -  Nov 29, 2006
Newsday,If it reaches market, Heplisav would have two competitors, Engerix-B from London-based GlaxoSmithKline PLC, and Recombivax from Whitehouse Station,

The 5-Sigma Report  -  Dec 5, 2006
Motley FoolWith only two approved vaccines currently available, Engerix-B and Merck's (NYSE: MRK) Recombivax HB, Dynavax could see some serious revenue coming their

Dynavax Shares Rise as Hepatitis B Shot Beats Glaxo's (Update2)  -  Nov 28, 2006
BloombergGlaxo's vaccine dominates the market with $450 million in annual sales, followed by Merck's Recombivax with $270 million, she said.

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional